Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study of the Safety and Efficacy of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

NCT06379646 is registered in ClinicalTrials.gov with China Immunotech (Beijing) Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06379646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06379646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study of the Safety and Efficacy of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Lead sponsor
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase
Not applicable
Overall status
Recruiting
Start date
April 24, 2024
Completion date
April 21, 2026
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-neutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, inflammatory myopathy, sjogren's syndrome, systemic lupus erythematosus, systemic sclerosis